Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex (PERSIST)
A Randomized, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Prevention of Recurrence in Subjects With Bipolar I Disorder
Sponsor: Sumitomo Pharma America, Inc.
Listed as NCT01358357, this PHASE3 trial focuses on Bipolar I Disorder and remains completed. Sponsored by Sumitomo Pharma America, Inc., it has been updated 8 times since 2011, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2023 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sumitomo Pharma America, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aichi, Japan , Atlanta, United States , Belgrade, Serbia , Bradenton, United States , Brno, Czechia , Brno-Bohunice, Czechia , Budapest, Hungary , Buenos Aires, Argentina , Burgas, Bulgaria , Charleston, United States and 76 more locations